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a b s t r a c t 
The tetrasaccharide heparan sulfate (HS) mimetic PG545, a clinical anti-cancer candidate, is an inhibitor 
of the HS-degrading enzyme heparanase. The kinetics of heparanase inhibition by PG545 and three 
structural analogues were investigated to understand their modes of inhibition. The cholestanol aglycon 
of PG545 signiﬁcantly increased afﬁnity for heparanase and also modiﬁed the inhibition mode. For the 
tetrasaccharides, competitive inhibition was modiﬁed to parabolic competition by the addition of the 
cholestanol aglycon. For the trisaccharides, partial competitive inhibition was modiﬁed to parabolic 
competition. A schematic model to explain these ﬁndings is presented. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical 
Societies. Open access under CC BY-NC-ND license.. Introduction 
Heparanase (HPSE) is an endo β- d -glucuronidase that cleaves hep- 
ran sulfate (HS) polymers in the extracellular matrix (ECM) and 
ontributes to tissue remodelling. HS is an important structural and 
hemical component of the ECM where they are attached to core 
roteins to form HS-proteoglycans (HSPG) such as perlecan, synde- 
an and glypican. During tissue remodelling, the ECM is degraded by 
roteases, including matrix metalloproteinases, and heparanase. This 
reaks down the structure of the ECM and, additionally, the degrada- 
ion of HS polymers also leads to the release of a variety of HS-binding 
ytokines including VEGF and FGF-2 which lead to altered physiolog- 
cal responses [ 1 ]. Heparanase is the only enzyme known to cleave 
S in the ECM, and for this reason it is at the nexus of these structural 
nd physiological transformations. 
Malignant cancers co-opt the tissue remodelling functions of hep- 
ranase during two processes that are important to tumour growth 
nd spread: angiogenesis and metastasis. Heparanase is important 
n the tissue remodelling and signalling involved in the generation 
f the new blood vessels required for the growth of tumours [ 2 ]. Abbreviations: ECM, extracellular matrix; HS, heparan sulfate; HSPG, heparan sul- 
ate proteoglycan; SE, standard error; SS , sum of squares; WST-1, 4-[3-(4-iodophenyl)- 
-(4-nitrophenyl)-2 H -5-tetrazolio]-1,3-benzene disulfonate. 
* Corresponding author. Address: Progen Pharmaceuticals, 2806 Ipswich Road, Darra, 
LD 4076, Australia. Tel.: + 61 7 3273 9134; fax: + 61 7 3375 1168. 
E-mail address: edwardh@progen-pharma.com (E. Hammond). 
211-5463 c © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of Europe            
ttp://dx.doi.org/10.1016/j.fob.2013.07.007 The ECM-degrading properties of this enzyme allow cancer cells to 
migrate through the ECM, a crucial step in the metastatic spread of 
cancer cells around the body to form new tumours [ 2 ]. The metastatic 
spread of tumours to parts of the body remote from the original tu- 
mour is a major cause of mortality from this disease [ 3 ]. 
Heparanase cleaves HS chains at speciﬁc glucuronic acid residues 
located within highly sulfated regions along the polymers. Interac- 
tions between the sulfate and carboxylate groups in these regions 
and patches of basic amino acid residues on the surface of heparanase 
coordinate the HS polymer and allow two glutamate residues in the 
catalytic site to hydrolyse the glycosidic bond. The carboxylate of 
the glucuronic acid at the point of cleavage and 2- N - and 6- O -sulfate 
groups on the glucosamine residues ﬂanking it constitute a trisac- 
charide sequence proposed to be necessary for heparanase binding 
and catalysis [ 4 , 5 ]. Although no three dimensional structure of hep- 
aranase has been published, homology modelling using similar pro- 
teins has suggested that the binding region could interact with a 
larger sequence of four or ﬁve saccharides within the HS chain [ 6 ]. 
Recent experimental evidence also supports the notion that saccha- 
ride residues ﬂanking the trisaccharide sequence may be involved in 
the binding of HS to heparanase [ 7 ]. 
Due to its importance in promoting tumour growth and metastatic 
spread, heparanase has been the target of numerous therapeutic de- 
velopment programs [ 8 ]. Two broad approaches characterise the de- 
sign of heparanase inhibiting compounds: small molecules binding 
speciﬁcally to the catalytic site and HS mimetics that bind in a similar 
manner as substrate thus preventing access to the catalytic site. The 
identiﬁcation of small molecule heparanase inhibitors has produced 
some interesting compounds [ 9 –11 ] though none have advanced to 
clinical trials and further progress has been hampered by the lack of a an Biochemical Societies. Open access under CC BY-NC-ND license.
E. Hammond et al. / FEBS Open Bio 3 (2013) 346–351 347 
Fig. 1. Structures of PG545 and the analogues examined here. Compound 1 is the trisaccharide analogue of PG545, while compounds 2 and 3 are the tetra- and trisaccharides 
sulfated at the site occupied by the cholestanol aglycon. 
Fig. 2. Inhibition of heparanase by PG545 and analogues measured using the fonda- 
parinux assay (panel A) and the ultraﬁltration assay (panel B). Fondaparinux assays 
contained 40 mM sodium acetate buffer (pH 5.0), 0.25 nM heparanase, 100 μM fonda- 
parinux and the indicated concentrations of inhibitors. Ultraﬁltration assay conditions 
as per Materials and methods. Data are means of 4 measurements (panel A) or 3 mea- 
surements (panel B) and error bars are standard errors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 structure for heparanase. In contrast, a number of HS mimetics have
shown promise and four with heparanase inhibition activity have en-
tered clinical trials: PI-88 [ 12 , 13 ], M402 [ 14 ], SST0001 [ 15 ] and PG545
[ 16 –18 ]. 
Despite the interest in developing heparanase inhibitors, few have
been subjected to a thorough analysis of their inhibition mode and,
as a result, linear competitive inhibition of heparanase by many HS
mimetics is assumed and not veriﬁed. Until recently this was partly
due to the lack of a heparanase assay suitable to conduct such anal-
yses, but with the publication of a simple colorimetric assay based
on the substrate fondaparinux, such an assay is now available [ 19 ].
Of the HS mimetics in clinical use, PG545 is the most appropriate forkinetic examination because it is a single molecular entity. The study
presented here has characterised the inhibition mode of PG545 and
compared it with three structural analogues to improve our under-
standing of how these molecules bind to heparanase ( Fig. 1 ). Such
data will also lead to a better understanding of the active site of this
important enzyme. 
2. Materials and methods 
PG545 and compound 1 were synthesised as previously reported
[ 20 , 21 ]. Compound 2 and compound 3 were synthesised from mal-
totetraose and maltotriose respectively, which were purchased from
Hayashibara Biochemical Laboratories, and sulfated according to the
general procedure reported previously [ 21 ]. 
Recombinant human heparanase was expressed in insect cells
[ 22 ] and then puriﬁed from the cell media into which it had
been secreted according to a previously described method [ 19 ]. The
tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2 H -
5-tetrazolio]-1,3-benzene disulfonate) was obtained from Dojindo.
Unless otherwise stated, all other reagents were obtained from
Sigma–Aldrich. 
2.1. Fondaparinux heparanase assays 
Fondaparinux heparanase assays were conducted as described
previously [ 19 ]. Assays were carried out in 96 well microplates (Costar
9018 EIA / RIA, Corning) pre-treated with a solution of 4% BSA in
phosphate-buffered saline containing 0.05% Tween 20 (PBST) for 2 h
at 37 ◦C. The plates were then washed three times with PBST and
shaken dry. Pre-treated plates were stored at 4 ◦C for up to 2 weeks
before use. Assays (100 μL) typically contained 40 mM sodium ac-
etate buffer (pH 5.0), 0.25 nM heparanase and varying concentrations
of fondaparinux and study compounds. The assays were prepared mi-
nus fondaparinux and allowed to equilibrate for 10 min before adding
the substrate to start catalysis. Incubation at 37 ◦C for 18 h was fol-
lowed by development with 100 μL of 1.69 mM WST-1 solution in
0.1 M NaOH at 60 ◦C for 1 h after which the absorbance at 584 nm
was measured (Fluostar Optima platereader, BMG Labtech). For IC 50
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Fig. 3. Double reciprocal analysis of PG545 inhibition of heparanase (panel A). Fonda- 
parinux assays conducted as per Section 2 . Data are means of 2 measurements. Lines 
were generated from the apparent K m and V max values. The slopes from panel A were 
replotted as a function of PG545 concentration in panel B. The solid line in panel B is 
the ﬁt of Eq. (4) to the data ( R 2 = 0.993, SS = 0.735) and the dotted line is the ﬁt of Eq. 
(2) ( R 2 = 0.950, SS = 5.450) for comparison. 
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Table 1 
Heparanase IC 50 values for PG545 and analogues measured using fondaparinux and 
ultraﬁltration assays. Errors are SE. 
Compound Fondaparinux assay Ultraﬁltration assay 
PG545 12.0 ± 0.7 nM 40.1 ± 6.0 nM 
1 19.8 ± 1.7 nM 84.0 ± 4.5 nM 
2 416 ± 25 nM 1650 ± 220 nM 
3 4820 ± 230 nM 13,500 ± 4100 nM nalysis, data were converted into % inhibition values by comparing 
o control assays containing no study compound. 
.2. Ultraﬁltration heparanase assays 
Heparanase activity was also measured using an ultraﬁltration as- 
ay based on a previously described method [ 23 ]. Reactions were set 
p in 1.5 mL microtubes in a volume of 200 μL containing 40 mM 
odium acetate buffer (pH 5.0), 0.005% Tween 20 (w / v), 4 nM hep- 
ranase, 5 μM [ 3 H]-HS and various concentrations of study com- 
ounds. Initially, all components except the [ 3 H]-HS substrate were 
llowed to equilibrate for 10 min. The assays were then started by 
dding [ 3 H]-HS and immediately 40 μL was taken, quenched with 
60 μL of 10 mM phosphate (pH 7.0) and the 200 μL transferred to 
 Microcon YM-10 ultraﬁltration device (Millipore) which was cen- 
rifuged at 14,000 g for 5 min. The solution that passed through the 
embrane (ﬁltrate) was retained. This sample was considered the t 0 
ample. The assays were aliquoted into 3 tubes of 40 μL each and these 
ere allowed to react at 37 ◦C for 18 h. The ﬁltration step was then re- 
eated after quenching with 160 μL of 10 mM phosphate (pH 7.0). The 
 0 ﬁltrate and the three ﬁltrate samples taken after 18 h ( t 18h ) were 
ounted for 3 H using Optiphase HiSafe 2 scintillant (Perkin Elmer) 
n a Microbeta 1450 counter (Wallac, Perkin Elmer). The difference 
etween the t 0 and the averaged t samples gave the amount of 18h heparanase activity. Relative inhibition assays were run with a hep- 
aranase standard assay which was identical in composition except no 
inhibitor was present, and the amount of heparanase inhibition in the 
other assays was determined by comparison with this standard. 
2.3. Data analysis 
To determine IC 50 values, % inhibition data were ﬁtted to the 
four parameter logistic equation. Kinetic constants, apparent K m and 
apparent V max , were determined by ﬁtting v versus [ S ] data to the 
Michaelis–Menten equation. Curve ﬁtting was performed by nonlin- 
ear regression using Prism 6.02 software (GraphPad Software) and 
R 2 and sum of squares ( SS ) analysis used to compare goodness of ﬁt 
of different models. Estimated kinetic parameters are quoted with 
standard errors (SE). 
3. Results 
The interaction of PG545 with the active site of heparanase was 
investigated by measuring the inhibition of this enzyme by PG545 
and three structural analogues using two heparanase assays that 
have different substrates and measurement methods. PG545 and its 
three analogues all inhibit heparanase activity in a concentration- 
dependant manner when measured using the fondaparinux assay 
( Fig. 2 A) or the ultraﬁltration assay ( Fig. 2 B). 
In terms of afﬁnity for heparanase, PG545 was the tightest binding 
followed by 1, 2 and 3 which had the lowest afﬁnity (IC 50 data in Table 
1 ). This afﬁnity ranking indicates that tetrasaccharide based com- 
pounds (PG545 and 2) have higher afﬁnity than their corresponding 
trisaccharide compounds. Also, the cholestanol-functionalised com- 
pounds (PG545 and 1) have higher afﬁnity than their correspond- 
ing tetra- and trisaccharides. The increased afﬁnity conferred by the 
cholestanol group suggests that this hydrophobic modiﬁcation allows 
PG545 and 1 bind to a hydrophobic patch or pocket near or within the 
heparanase active site in addition to binding to the basic amino acid 
residues involved in substrate binding. The IC 50 values for compound 
2 show reasonable agreement with a previously published IC 50 value 
of 10 μg / mL (4700 nM) given the different assays and substrates [ 24 ]. 
All inhibitors except compound 3 showed complete inhibition of 
heparanase at saturating concentrations. In contrast, 3 inhibited ap- 
proximately 80% of heparanase activity at concentrations approxi- 
mately 40 times the measured IC 50 values in both assays. Competitive 
inhibition of heparanase by HS mimetics is typically assumed, thus 
incomplete inhibition, as observed with 3, is unexpected. 
Given the signiﬁcant differences in afﬁnity and the incomplete in- 
hibition by compound 3, the inhibition modes of PG545 and its ana- 
logues were investigated further. The fondaparinux assay was used for 
this analysis because it utilises an homogenous substrate which has 
only one heparanase cleavage site per molecule. While this assay does 
not measure initial reaction velocities, an assumption inherent in the 
models used to characterise the data, it does conform to Michaelis–
Menten kinetics [ 19 ]. The K m of 3.6 ± 0.5 μM was measured for the 
interaction of fondaparinux with heparanase and used in subsequent 
analyses. The value is lower than previously reported which reﬂects 
the improved handling of this assay since its development and initial 
publication [ 19 ]. 
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Fig. 4. Double reciprocal analysis of heparanase inhibition by compounds 1, 2 and 3 (panels A, C and E). Fondaparinux assays conducted as per Section 2 . Data are means of 2 
measurements. Lines were generated from the apparent K m and V max values. The slopes from panels A, C and E were replotted as a function of inhibitor concentration in panels 
B, D and F respectively. The solid line in panel B is the ﬁt of Eq. (4) to the slopes data ( R 2 = 0.964, SS = 0.972) and the dotted line is the ﬁt of Eq. (2) ( R 2 = 0.880, SS = 3.281) for 
comparison. The solid line in panel D represents the global ﬁt of the competitive inhibitor rate Eq. (5) to the velocity data set. The solid line in panel F is the ﬁt of Eq. (6) to the 
slopes data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Double reciprocal analysis of a matrix of fondaparinux heparanase
assays at a range of substrate and PG545 concentrations indicates that
this compound is a competitive inhibitor of heparanase ( Fig. 3 A). In-
terestingly, when the slopes of the double reciprocal plot are replotted
against inhibitor concentration, the resulting curved response indi-
cates that PG545 is a parabolic competitive inhibitor ( Fig. 3 B). These
data were compared to the parabolic competitive inhibition model
[ 25 ]. 
v = V max · S 
K m 
(
1 + 2 
(
I 
K i 
)
+ 1 
α
(
I 
K i 
)2 )
+ S 
(1)
Eq. (1) was converted into the following form for analysis of the
slope data ( Fig. 3 B, dotted line, R 2 = 0.950, SS = 5.450). 
Slope = 
K m 
(
1 + 2 
(
I 
K i 
)
+ 1 
α
(
I 
K i 
)2 )
V max 
(2)
A better ﬁt to the data, however, was achieved using the Hill-type
model of Cao et al. [ 26 ]. 
v = V max · S 
K m 
(
1 + I n 
K n i 
)
+ S 
(3)
This equation was also rearranged for analysis of the slope data
( Fig. 3 B, solid line, R 2 = 0.993, SS = 0.735). 
Slope = 
K m 
(
1 + I n 
K n i 
)
V 
(4)
max The K i and Hill coefﬁcient ( n ) determined from the curve ﬁt were
4.44 ± 0.30 nM and 2.98 ± 0.16 respectively. 
The kinetics of the three PG545 analogues were analysed in a
similar manner. Compound 1, which shares the cholestanol functional
group with PG545, shows similar parabolic competitive inhibition
( Fig. 4 A and B). Once again, the Hill-type inhibition model ( R 2 = 0.964,
SS = 0.972) showed a better ﬁt to the data than the conventional
parabolic competitive model ( R 2 = 0.880, SS = 3.281). The resulting
K i and n determined from the curve ﬁt were 9.82 ± 1.12 nM and
3.62 ± 0.44 respectively. 
The two analogues without the cholestanol group, compounds 2
and 3, showed different kinetics. The tetrasaccharide (2) showed lin-
ear competitive inhibition of heparanase ( Fig. 4 C and D) whereas the
trisaccharide (3) showed partial competitive inhibition as indicated
by the hyperbolic response of the double reciprocal slopes when plot-
ted against inhibitor concentration ( Fig. 4 E and F). The competitive
inhibition rate Eq. (5) was ﬁtted to velocity data set for compound 2
using global nonlinear regression. From this ﬁt, the K i of heparanase
inhibition by compound 2 was estimated to be 12.4 ± 0.4 nM. 
v = V max · S 
K m 
(
1 + I K i 
)
+ S 
(5)
The conclusion that compound 3 is a partial competitive inhibitor
of heparanase is supported by the earlier observation that it failed
to completely inhibit the enzyme even as inhibitor concentration in-
creased to approximately 40 times the IC 50 : such behaviour is charac-
teristic of partial competitive inhibitors. Because partial competitive
inhibitors can bind to both free enzyme and enzyme-substrate com-
plex, the relative afﬁnities of compound 3 for these two forms of
350 E. Hammond et al. / FEBS Open Bio 3 (2013) 346–351 
Fig. 5. Schematic model of the three modes of heparanase inhibition displayed by 
PG545 and its three analogues. Competitive inhibitors, such as compound 2, straddle 
the entire substrate binding region and completely occlude the catalytic site (panel A). 
Partial competitive inhibitors which are not large enough to bridge the two HS binding 
patches, such as compound 3, allow substrate access to the catalytic site (panel B). 
Parabolic competitive inhibitors, such as PG545 and compound 1, bind two molecules, 
the second molecule binding with higher afﬁnity (panel C). 
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ieparanase were estimated by ﬁtting a modiﬁed form of the partial 
ompetitive inhibitor (Eq. (6) ) to the data in Fig. 4 F. 
lope = K m 
V max 
(
1 + I K i 
)
(
1 + 1 
αK i 
) (6) 
rom the curve ﬁt the K i for compound 3 was estimated to be 
97 ± 27 nM and the α value 2.8 ± 1.1 indicating that this compound 
as considerably higher afﬁnity for the unoccupied heparanase active 
ite compared to the substrate bound active site. 
. Discussion 
Heparanase is an important protein involved in cancer spread and 
alignancy that has been the target of drug development programs 
ince its discovery. A variety of HS mimetics have been employed 
s inhibitors of this enzyme, both experimentally and in clinical tri- 
ls. PG545 has already entered cancer clinical trials and is expected 
o re-commence trials in the near future. Understanding the bind- 
ng modes of HS mimetics to heparanase is, therefore, of considerable importance. The lessons learned from studying the interaction of hep- 
aranase with these inhibitors and its substrate may also be applicable 
to other important enzymes that have polymeric substrates. 
PG545 and its three structural analogues possess three distinct 
modes of heparanase inhibition. This diversity is unusual consider- 
ing, ﬁrstly, their similarity and, secondly, that heparanase is thought 
to exist as a heterodimer with one active site, thus precluding in- 
teraction between active sites. A structure of heparanase has not 
been published although information about the three-dimensional 
arrangement of important parts of the protein has been gleaned from 
comparative modelling of the sequence based upon the structures 
of related proteins [ 27 , 6 , 28 ]. The enzymatic domain of heparanase 
comprises an ( α/ β) 8 TIM-barrel with two catalytic glutamate residues 
located at the surface, close to the rotational axis of this motif. Basic 
amino acid residues, which are involved in HS binding, are located in 
two patches either side of the active site. 
Although the exact positions and distances between these residues 
is unknown, heparanase interacts with at least three and possibly ﬁve 
saccharide units of substrate HS polymer indicating that the substrate 
binding region is quite large. Given the three modes of inhibition ki- 
netics observed here and our knowledge of the substrate-binding re- 
gion, a schematic model of the binding of these ligands to heparanase 
can be proposed ( Fig. 5 ). Conventional competitive HS mimetic in- 
hibitors, such as compound 2, are able to bridge the two patches of 
HS binding basic residues and, although they probably do not have 
any inherent afﬁnity for the catalytic site, they obstruct it preventing 
substrate from docking and completely inhibit catalysis ( Fig. 5 A). If 
the HS mimetic is not sufﬁciently long enough to bridge the two bind- 
ing patches, it may bind to only one and, leaving the other binding 
patch and the catalytic site unobstructed, allow catalysis to proceed 
even when the population of enzyme active sites is fully occupied by 
inhibitors ( Fig. 5 B). It is this behaviour – partial competitive inhibi- 
tion – that was observed with the shorter of the two-saccharide chain 
analogues, the trisaccharide 3. Similar behaviour has been seen pre- 
viously with sulfated di- and trisaccharide inhibitors of heparanase 
[ 29 ]. These latter compounds have a mannose backbone in contrast 
to the glucose based compounds presented here, indicating that this 
inhibition behaviour is not speciﬁc to the current compounds and it 
is likely, therefore, that the same behaviour would be observed with 
other similar sized HS-mimetics. 
In contrast to compounds 2 and 3, PG545 and its trisaccharide 
analogue 1 inhibit heparanase with parabolic competitive kinetics. 
Several prerequisites must be accommodated when formulating a 
mechanistic model to describe this behaviour. Firstly, the sulfated 
trisaccharide is transformed by the addition of a cholestanol group 
from the partial competitive inhibitor 3 into a higher afﬁnity ligand 
that completely inhibits heparanase at 100% occupancy. This suggests 
that the cholestanol group interacts with, or obscures, the catalytic 
site and that this interaction contributes signiﬁcantly to the afﬁn- 
ity of compound 1. Homology modelling has identiﬁed a channel of 
hydrophobic residues surrounding the catalytic residues forming a 
possible binding site for the cholestanol group [ 28 ]. 
Secondly, parabolic competitive inhibitors bind to two sites on 
the enzyme and each interaction is sufﬁcient to completely prevent 
catalysis. The two patches of HS binding residues ﬂanking the catalytic 
site of heparanase are likely candidates with molecules of PG545 or 
1 binding to these patches in such a way that one or both of the 
cholestanol groups obscures the catalytic site. 
Thirdly, the binding of the ﬁrst parabolic competitive inhibitor 
molecule increases the afﬁnity of the subsequent molecule’s interac- 
tion with the enzyme. This could result from a conformational change 
in heparanase induced by the binding of the cholestanol group which 
increases the afﬁnity between the transiently modiﬁed second site 
and another inhibitor molecule. An alternative explanation is that the 
bound cholestanol group of the ﬁrst inhibitor molecule serves as a 
binding site for the same moiety of the second inhibitor and once 
E. Hammond et al. / FEBS Open Bio 3 (2013) 346–351 351 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 bound, the ﬁrst cholestanol group becomes buried and inaccessible
to solvent ( Fig. 5 C). Such an arrangement, given the hydrophobic na-
ture of this functional group, is probably energetically favourable.
This latter explanation also provides a mechanism to explain the in-
creased afﬁnity for the second inhibitor’s binding and it is, therefore,
considered the more likely of the two. 
Parabolic competitive and partial competitive are generally quite
rare modes of enzyme inhibition. Even rarer and more interesting
is the ﬁnding that structurally related compounds can show such a
range of divergent modes of enzyme inhibition. This discovery high-
lights the added complexity of an interaction between an enzyme
and a polymeric substrate. The absence of a three dimensional hep-
aranase structure, long lamented by heparanase researchers, contin-
ues to hamper our understanding of the interactions between hep-
aranase and substrate. This gap in our knowledge presents difﬁculties
to those attempting to target this enzyme using HS mimetics, an ap-
proach which has, nevertheless, shown some promise with several of
these compounds entering clinical trials for the treatment of cancer.
The improved understanding of the interaction of heparanase with
HS mimetics gained from the data presented here can only increase
our ability to construct more efﬁcient inhibitors of this important
enzyme. 
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